Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 11, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

[Interleukin-6 implication in prostate cancer].

Aurélie Cabrespine1, Jacques-Olivier Bay, Pierre Verrelle

  • 1Service de thérapie cellulaire et d'hématologie clinique adultes, Pavillon Villemin-Pasteur, Hôtel-Dieu boulevard Léon-Malfreyt, 63058 Clermont-Ferrand. acabrespine@chu-clermontferrand.fr

Bulletin Du Cancer
|September 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential biological effects of scattered versus scanned clinical proton beams on Ewing sarcoma models.

Radiation oncology (London, England)·2026
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

[Do chemotherapies still have a place in the era of precision medicine?]

Bulletin du cancer·2026

Interleukin-6 (IL-6) significantly promotes prostate cancer progression, particularly in the hormone-refractory phase. Targeting IL-6 pathways offers a promising new therapeutic strategy for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Context:

  • Prostate cancer exhibits elevated Interleukin-6 (IL-6) levels, especially during hormone-refractory progression.
  • IL-6 signaling pathways (MAPK, STAT3, PI3K-Akt) are implicated in key cancer mechanisms.

Purpose:

  • To elucidate the role of IL-6 in prostate cancer progression.
  • To explore IL-6's influence on androgen receptor activation and neuroendocrine differentiation.

Summary:

  • IL-6 promotes prostate cancer by activating androgen receptors without ligands, inhibiting apoptosis, and enhancing invasion and angiogenesis.
  • IL-6 also induces neuroendocrine differentiation, a process linked to prostate cancer pathogenicity.
  • Key signaling pathways involved include MAPK, STAT3, and PI3K-Akt.

Related Experiment Videos

Last Updated: Jul 11, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Impact:

  • IL-6 is identified as a critical factor in prostate cancer progression.
  • IL-6 represents a potential novel therapeutic target for prostate cancer treatment.